胰岛素与胰高血糖素样肽-1受体激动剂联合治疗2型糖尿病的未来——是否具有优势？
The Future of Combination Therapies of Insulin with a Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes - Is it Advantageous?
作者信息
Gallwitz Baptist
机构信息
Professor of Medicine, Department of Medicine IV, Eberhard Karls University, Tübingen, Germany.
出版信息
Eur Endocrinol. 2014 Aug;10(2):98-99. doi: 10.17925/EE.2014.10.02.98. Epub 2014 Aug 28.
Abstract
Safe and effective therapies for type 2 diabetes are needed to reduce the burden of late complications and costs associated with this chronic disease. Hypoglycaemia and body weight gain are side effects and limitations of the therapy with insulin and/or sulphonylureas. Recently, the combination of glucagon-like peptide-1 (GLP-1) receptor agonists and insulin has become available, which is associated with good efficacy and less risk for hypoglycaemia and weight gain. This editorial discusses the strategies to escalate treatment in type 2 diabetes in view of this novel combination and discusses its placement within the therapeutic algorithm of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Recent developments to simplify this combination therapy are also dealt with.
摘要
需要安全有效的2型糖尿病治疗方法来减轻与这种慢性病相关的晚期并发症负担和成本。低血糖和体重增加是胰岛素和/或磺脲类药物治疗的副作用和局限性。最近，胰高血糖素样肽-1（GLP-1）受体激动剂与胰岛素的联合用药已可使用，其疗效良好，低血糖和体重增加风险较低。本社论鉴于这种新的联合用药方式，讨论了2型糖尿病强化治疗的策略，并讨论了其在美国糖尿病协会（ADA）和欧洲糖尿病研究协会（EASD）治疗算法中的位置。还探讨了简化这种联合治疗的最新进展。
相似文献
1
The Future of Combination Therapies of Insulin with a Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes - Is it Advantageous?胰岛素与胰高血糖素样肽-1受体激动剂联合治疗2型糖尿病的未来——是否具有优势？
Eur Endocrinol. 2014 Aug;10(2):98-99. doi: 10.17925/EE.2014.10.02.98. Epub 2014 Aug 28.
2
Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.2型糖尿病中胰高血糖素样肽-1受体激动剂：随机临床试验的荟萃分析。
Eur J Endocrinol. 2009 Jun;160(6):909-17. doi: 10.1530/EJE-09-0101. Epub 2009 Mar 24.
3
Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus.胰高血糖素样肽 1 受体激动剂在 1 型糖尿病中的应用。
Am J Health Syst Pharm. 2019 Oct 15;76(21):1739-1748. doi: 10.1093/ajhp/zxz179.
4
Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.GLP-1 受体激动剂和二肽基肽酶-4 抑制剂作为二甲双胍的附加疗法在 2 型糖尿病患者中的血糖疗效：综述和荟萃分析。
Diabetes Obes Metab. 2012 Aug;14(8):762-7. doi: 10.1111/j.1463-1326.2012.01603.x. Epub 2012 Apr 24.
5
The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes.GLP-1 受体激动剂在 2 型糖尿病治疗中的安全性和耐受性。
Int J Clin Pract. 2010 Sep;64(10):1402-14. doi: 10.1111/j.1742-1241.2010.02465.x.
6
The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.胰高血糖素样肽-1受体激动剂的胰腺外效应：聚焦于心血管系统、胃肠道和中枢神经系统
Diabetes Obes Metab. 2014 Aug;16(8):673-88. doi: 10.1111/dom.12251. Epub 2014 Jan 16.
7
Novel Therapeutic Approaches in Diabetes.糖尿病的新型治疗方法
Endocr Dev. 2016;31:43-56. doi: 10.1159/000439372. Epub 2016 Jan 19.
8
New drugs for type 2 diabetes mellitus: what is their place in therapy?2型糖尿病的新药：它们在治疗中的地位如何？
Drugs. 2008;68(15):2131-62. doi: 10.2165/00003495-200868150-00005.
9
Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting.在丹麦环境下，每周一次司美格鲁肽与度拉鲁肽、艾塞那肽缓释剂、利拉鲁肽和利司那肽治疗2型糖尿病患者的成本效益分析
Diabetes Ther. 2019 Aug;10(4):1297-1317. doi: 10.1007/s13300-019-0630-6. Epub 2019 May 16.
10
Evaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom.评估在英国每日使用胰高血糖素样肽-1（GLP-1）受体激动剂治疗2型糖尿病的长期成本效益
Diabetes Ther. 2017 Feb;8(1):129-147. doi: 10.1007/s13300-016-0219-2. Epub 2017 Jan 5.
引用本文的文献
1
RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020.2020年RSSDI-ESI 2型糖尿病管理临床实践建议
Indian J Endocrinol Metab. 2020 Jan-Feb;24(1):1-122. doi: 10.4103/ijem.IJEM_225_20.
2
Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement.2型糖尿病患者抗高血糖药物和胰高血糖素样肽1受体激动剂的依从性：临床后果及改善策略
Patient Prefer Adherence. 2018 May 7;12:707-719. doi: 10.2147/PPA.S151736. eCollection 2018.
3
Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes.基础胰岛素/胰高血糖素样肽-1受体激动剂固定比例复方制剂（德谷胰岛素利拉鲁肽和甘精胰岛素利司那肽）用于2型糖尿病管理的理论依据、起始治疗及滴定方法
Diabetes Ther. 2017 Aug;8(4):739-752. doi: 10.1007/s13300-017-0287-y. Epub 2017 Jul 18.
本文引用的文献
1
Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.胰高血糖素样肽 1 受体激动剂或速效胰岛素联合优化基础胰岛素治疗 2 型糖尿病。
Diabetes Care. 2014 Oct;37(10):2763-73. doi: 10.2337/dc14-0876. Epub 2014 Jul 10.
2
One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target.根据糖化血红蛋白目标值，在二甲双胍的基础上加用利拉鲁肽，之后再换用胰岛素地特胰岛素，可实现 2 型糖尿病患者的 1 年持续血糖控制和体重减轻。
J Diabetes Complications. 2013 Sep-Oct;27(5):492-500. doi: 10.1016/j.jdiacomp.2013.04.008. Epub 2013 Jun 6.
3
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.GLP-1 受体激动剂用于 2 型糖尿病的个体化治疗。
Nat Rev Endocrinol. 2012 Dec;8(12):728-42. doi: 10.1038/nrendo.2012.140. Epub 2012 Sep 4.
4
Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings.将 GLP-1 受体激动剂与胰岛素联合使用：治疗原理和临床发现。
Diabetes Obes Metab. 2013 Jan;15(1):3-14. doi: 10.1111/j.1463-1326.2012.01628.x. Epub 2012 Jun 29.
5
Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets.利拉鲁肽序贯强化二甲双胍治疗 2 型糖尿病，根据 A1C 目标值随机加用基础胰岛素。
Diabetes Care. 2012 Jul;35(7):1446-54. doi: 10.2337/dc11-1928. Epub 2012 May 14.
6
Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).一项在亚洲 2 型糖尿病患者中进行的随机、双盲、安慰剂对照试验，评估每日一次 GLP-1 受体激动剂利西那肽在基础胰岛素联合或不联合磺脲类药物治疗血糖控制不佳的患者中的疗效（GetGoal-L-Asia）。
Diabetes Obes Metab. 2012 Oct;14(10):910-7. doi: 10.1111/j.1463-1326.2012.01618.x. Epub 2012 May 30.
7
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).2型糖尿病高血糖管理：以患者为中心的方法。美国糖尿病协会（ADA）和欧洲糖尿病研究协会（EASD）的立场声明。
Diabetologia. 2012 Jun;55(6):1577-96. doi: 10.1007/s00125-012-2534-0. Epub 2012 Apr 20.
8
Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.甘精胰岛素联合艾塞那肽治疗 2 型糖尿病的真实世界结局。
Curr Med Res Opin. 2012 Mar;28(3):439-46. doi: 10.1185/03007995.2012.654850. Epub 2012 Jan 23.
9
Pharmacotherapy: GLP-1 analogues and insulin: sound the wedding bells?药物治疗：胰高血糖素样肽-1类似物与胰岛素：敲响婚礼钟声？
Nat Rev Endocrinol. 2011 Apr;7(4):193-5. doi: 10.1038/nrendo.2011.30. Epub 2011 Feb 22.
10
Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications.基于肠降血糖素的 2 型糖尿病治疗药物：特性、功能和临床意义。
Am J Med. 2011 Jan;124(1 Suppl):S3-18. doi: 10.1016/j.amjmed.2010.11.002.
Zotero 插件